Lung Cancer

Following treatment failure on frontline TKIs in EGFR+ advanced NSCLC, experts consider biomarker testing to inform second-line treatment.

Current considerations that affect the choice of frontline therapy for patients with small cell lung cancer with the availability of novel systemic therapies.

In the past 2 years, key data from clinical trials in advanced lung cancer have demonstrated that immunotherapy has expanded the bounds of the armamentarium for the treatment of several lung cancers.

Upal Basu Roy, PhD, MPH, discusses addressing barriers to biomarker testing in lung cancer.

Russell Kenneth Hales, MD, discusses investigational treatment strategies that have the potential to build upon the positive results of the phase 3 PACIFIC trial in stage III non–small cell lung cancer.

Surgical resection remains the key treatment modality for early-stage non–small cell lung cancer; however, both systemic adjuvant and neoadjuvant therapeutics are options that have value for patients.

Jacob Sands, MD, physician, discusses the importance of next-generation sequencing testing in lung cancer.

The field of non–small cell lung cancer has exploded with continuous advances in targeted therapies directed toward key molecular alterations, including rare mutations like MET exon 14 skipping mutations, RET rearrangements, and ROS1 mutations.

In 2021, 13 novel agents were approved across hematology/oncology. Additionally, there were many other notable approvals—whether they were new formulations, expanded indications, or biosimilar approvals—across tumor types that expanded accessibility for varying patient populations.

Hossein Borghaei, DO, MS; and Martin Reck, MD, PhD, discuss factors that affect treatment selection in NSCLC, and the role of molecular and biomarker testing.

Primary and metastatic brain tumors present a significant therapeutic challenge, in large part because they are protected by the blood-brain barrier, a highly restrictive interface between the bloodstream and the brain that prevents most drugs from accessing the brain parenchyma.

Experts review frontline combination approaches with bevacizumab in EGFR+ advanced non–small cell lung cancer.

A comprehensive discussion on frontline treatment options for patients with EGFR+ advanced non–small cell lung cancer.

Symptoms and risk factors associated with small cell lung cancer, and recommendations for staging patients with newly diagnosed disease.

The European Commission has granted a marketing authorization for lorlatinib for use as a single agent in the treatment of adult patients with ALK-positive advanced non–small cell lung cancer who did not receive a prior ALK inhibitor.

The identification of actionable oncogenetic drivers in patients with non–small cell lung cancer affords clinicians the opportunity to use targeted agents to optimize outcomes.

Raymond U. Osarogiagbon, MD, FACP, discusses geographic disparities in lung cancer.

Sandip P. Patel, MD, discusses optimizing molecular testing for EGFR mutations in lung cancer.

Although advances in metastatic non–small cell lung cancer treatment have dramatically impacted cancer mortality, the translation of these approaches to earlier-stage NSCLC has just begun to bear fruit.

Nathaniel Ivanick, MD, FCCP, explains advancements in the use of robotic navigational bronchoscopy for the diagnosis of early-stage lung cancer.

Closing out their discussion on resectable NSCLC, experts review multidisciplinary care strategies and the role of neoadjuvant therapy in patients identified for resection.

In light of evolving treatment options for resectable non–small cell lung cancer, panelists discuss biomarker testing to guide adjuvant therapy in the postoperative setting.

The FDA has accepted for review a supplemental biologics license application for cemiplimab-rwlc in combination with chemotherapy in the frontline treatment of patients with advanced non–small cell lung cancer.

Experts provide clinical pearls on treating Lambert-Eaton myasthenic syndrome and small cell lung cancer and share upcoming advances and trials they look forward to.

Hope S. Rugo, MD, FASCO, Rita Nanda, MD, William J. Gradishar, MD, and Tiffany A. Traina, MD discuss the selective immunomodulating microtubule-binding agent plinabulin, plus several other novel chemoprotective therapies under exploration, including trilaciclib.

Paying particular attention to the specific type of gene mutation on a molecular testing report is critical in an era of increasing genomic complexity in non–small cell lung cancer.

Experts consider if there’s a role for the continued use of first-generation TKIs in patients with resected EGFR-positive non–small cell lung cancer.

Shared insight on the clinical implications of the ADAURA trial, which tested osimertinib as adjuvant therapy following resection in patients with EGFR-positive NSCLC.

Konstantinos Arnaoutakis, MD, discusses new strategies in the management of ALK-positive non–small cell lung cancer, frontline immunotherapy, targeting EGFR, and biomarkers and targeted therapies in early-stage and advanced disease.

The addition of ADXS-503 to the treatment of patients with metastatic non–small cell lung cancer who were progressing on pembrolizumab (Keytruda) resulted in encouraging responses and durable disease control, according to findings from the phase 1/2 trial.